Real-world data on niraparib maintenance treatment in patients with non-gBRCA mutated platinum-sensitive recurrent ovarian cancer.
Bente VilmingJørgen Fallås DahlAnne Gry BentzenVibeke Anett IngebrigtsenElisabeth Berge NilsenIngvild VistadAnne DørumOlesya SolheimLine BjorgeManuela ZucknickGuro AuneKristina LindemannPublished in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2023)
In a real-world setting, niraparib maintenance treatment in patients with non-gBRCA1/2 mutated recurrent platinum-sensitive ovarian cancer showed effectiveness comparable with published phase III studies and acceptable safety. Individualized dosing is essential to minimize adverse events. CA125 levels at start of niraparib treatment may help to estimate the individual prognosis.